AnnJi Pharmaceutical Co., Ltd.

AnnJi Pharmaceutical (TPEX: 7754), founded in 2014 using core technology licensed from National Taiwan University, is a clinical-stage biotech developing first-in-class small molecule therapies for dermatology, neurology, and rare diseases. Lead candidate AJ201 showed positive Phase 1/2a results for Spinal and Bulbar Muscular Atrophy (SBMA/Kennedy disease) in May 2025.